Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM)

Autores: Berdeja, J. G.; Krishnan, A. Y.; Oriol, A.; van de Donk, N. W. C. J.; Rodríguez Otero, Paula; Askari, E.; Mateos, M. V.; Minnema, M. C.; Costa, L. J.; Verona, R.; Girgis, S.; Prior, T.; Hilder, B.; Russell, J. S.; Goldberg, J. D.; Chari, A.